Today's Rundown Bayer moves to refocus on its core pharma R&D, cutting 900 research jobs AstraZeneca’s TLR9 oligonucleotide misses goal in asthma phase 2 Lundbeck and Otuska’s brexpiprazole hits the mark in PTSD trial [Sponsored] Minimal Residual Disease: Application in Blood Cancers Principia chalks up a win for its BTK autoimmune program Editas bags $25M from Allergan as FDA signs off on human CRISPR trial EuroBiotech Report—Novartis HQ move, Vectura fail, Hookipa pact, MHRA and Stallergenes FiercePharmaAsia—Gene-edited babies; Takeda-Shire countdown; Celltrion’s Rituxan biosim Chutes & Ladders—Abeona fires CEO Carsten Thiel Featured Story | Thursday, November 29, 2018 Bayer aims to comprehensively restructure its pharmaceutical R&D and consumer health operations, a long-awaited move that the company says will refocus assets to its core life science businesses over the coming years. |
|
| Top Stories Friday, November 30, 2018 A phase 2a trial of AstraZeneca’s AZD1419 has missed its primary endpoint. AstraZeneca moved the Dynavax-partnered TLR9 agonist into the trial in the belief it could improve time to loss of asthma control in patients with eosinophilic, moderate-to-severe forms of the disease. Friday, November 30, 2018 Lundbeck and Otuska’s brexpiprazole-sertraline cocktail has hit the mark in a post-traumatic stress disorder phase 2. The data give Lundbeck a boost at a time when its recently installed CEO is hunting for ways to improve on lackluster growth forecasts. Monday, November 26, 2018 A diagnosis of chronic lymphocytic leukemia (CLL) can mean a long road with many twists and turns as patients try to achieve long-term remission from this chronic, complex and progressive form of blood cancer. Friday, November 30, 2018 Newly listed biotech Principia Biopharma has started a phase 3 program for its lead BTK inhibitor in the rare autoimmune disease pemphigus after hitting the target in a midstage trial. Friday, November 30, 2018 After a year’s delay, Editas Medicine is finally back on track. The gene-editing biotech announced Friday the FDA has OK’d its IND application and that it will start enrolling patients in a phase 1/2 trial of its CRISPR-based treatment for LCA10, a rare form of blindness. Thursday, November 29, 2018 In this week's EuroBiotech Report, Novartis to move U.K. headquarters, Vectura fails phase 3 test and Hookipa inks R&D pact and more. Friday, November 30, 2018 A Chinese researcher claims he used CRISPR to make the world's first gene-edited babies, triggering an outcry; Takeda's Shire buyout faces last-minute drama from its ex-chairman and rebel shareholders; Celltrion and Teva won a first FDA nod for a Rituxan biosimilar; and more. Friday, November 30, 2018 Abeona ejects CEO Carsten Thiel for "personal misconduct"; MHRA CEO Ian Hudson will leave the agency in the wake of Brexit; Lilly CMO Robert Brown is picked to lead Brickell Bio; and Janssen's discovery head joins Incyte as its CSO leaves for Third Rock. Those moves plus more hirings, firings and retirings throughout the industry. This week's sponsor is Johnson & Johnson Innovation. | | | Enrollment Showcase | Sponsored by: Biotech Primer BioBasics is an intensive two-day course starting with a review of the healthcare sectors and the scientific concepts required for understanding the biopharma industry, then delves into the cause of genetic and infectious disease, diagnostics and strategies used to mitigate disease and finally the latest innovations in biopharma are explained. Register today! |
|
| Resources Sponsored by: Coupa Software Learn how Becton Dickinson implemented Coupa to create an easy-to-use purchase to pay process that increased efficiency across the organization. Sponsored by: Almac Diagnostic Services, part of the Almac Group Download the whitepaper to learn more. Sponsored by: Reprints Desk, Inc. Learn how to fast-track your research workflows! Sponsored by: Veeva Industry Research: Read the 2018 Unified Clinical Operations Report to find out how pharmas and CROs are evolving clinical trial processes. Sponsored by: Applied BioMath This on-demand webinar introduces a quantitative systems pharmacology (QSP) model of targeted anabolic growth factors for intra-articular injection for the treatment of diseased joints. Sponsored by: Oracle Health Sciences New research reveals more than 50% of clinical data management professionals surveyed, are not confident in the quality and completeness of their clinical trial data. Sponsored by: Veradigm New Case Study – Leveraging Real-World Evidence From EHR to Assess Migraine Management Sponsored by: Signals Analytics What does data tell us about the future of cell & gene therapy? Sponsored by: Patheon, part of Thermo Fisher Scientific Download the whitepaper to learn more. Sponsored by: Outer Edge Technology Outer Edge Technology specializes in designing and managing regulated cloud-based infrastructures for the Life Sciences Industry – typically leveraging the AWS and Microsoft Azure platforms. Sponsored by: Catalent In the United States, it takes an average of 12 years for an experimental drug to travel from the laboratory to a patient’s medicine cabinet. The average cost to research and develop a successful drug is approximately $2.6 billion. Sponsored by: Catalent Today’s scientists are under significant time pressure to accelerate their compound from discovery to the clinic. Such pressure can often lead research organizations to adopt short-term thinking and overlook the downstream realities of drug development. Sponsored by: Catalent What is the fastest way to success? It is critical that drug developers execute several elements related to planning, investment, and understanding of the risks, risk tolerance, and pitfalls inherent in the drug development program. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. Sponsored by: Catalent Develop a basic understanding of principles and concepts of bioavailability of oral drugs. Drug Approval, Manufacturing Quality & Regulation 2018 | Online Compliance Training for Professionals working in APAC region March 4-7, 2019 | Singapore FierceBiotech Executive Breakfast at the J.P. Morgan Healthcare Conference 2019 January 8, 2019 | The Fairmont Hotel | San Francisco, CA BioBasics: Biotech For The Non-Scientist December 5-6, 2018 | Boston, MA Phacilitate Leaders World 2019 January 22-25, 2019 I Hyatt Regency, Miami Molecular Medicine Tri-Conference March 10-15, 2019 | San Francisco, CA |